Loading ...
Any other condition or clinically significant abnormal findings during the physical examination , assessment of medical history ( e.g. previous anaphylactic reactions or recent severe systemic illness , , cognitive impairment ) , orresultsclinical laboratory test
Any other condition or clinically significant abnormal findings during the physical examination , assessment of medical history ( e.g. cognitive impairment ) orresultsclinical laboratory test
Changes from baseline inresultsclinical laboratory test
lab professionals(passive) created byclinical lab testing
the use of different measurement methods(passive) caused byclinical laboratory test results
a group of regulations promulgated by the U.S. Food and Drug Administration ( FDAsetclinical laboratory testing standards
laboratory professionals(passive) created byclinical lab testing
a recognized accrediting agency(passive) set byclinical laboratory testing standards
the U.S. government 's Clinical Laboratory Improvement Amendments ( CLIA ) of 1988(passive) set byclinical laboratory testing standards
For example , I usedto designclinical laboratory tests
Urdu Epub Download Scoutingdesignedfor Clinical Laboratory Tests
safe participation in the study Diagnosed and / or treated tumor ( except basal cell skin cancer , carcinoma in situ of the cervix or prostate cancer in situ ) in the last five yearsmight preventsafe participation in the study Diagnosed and / or treated tumor ( except basal cell skin cancer , carcinoma in situ of the cervix or prostate cancer in situ ) in the last five years
optic neuritis or vasculitiscould causeoptic neuritis or vasculitis
to help detectdesignedto help detect
statistical associations across omics layersto createstatistical associations across omics layers
better outcomes for patients with these conditions ... driving earlier treatment , reducing complications , and eventually supporting slower disease progressioncreatebetter outcomes for patients with these conditions ... driving earlier treatment , reducing complications , and eventually supporting slower disease progression
a serotype characterisation which matched this strain to the 0104 : H4 pathogendiscovereda serotype characterisation which matched this strain to the 0104 : H4 pathogen
70 % of medical decisionsinfluence70 % of medical decisions
to obtain genetic information for direct therapeutic benefits to the subject or his / her blood relativesdesignedto obtain genetic information for direct therapeutic benefits to the subject or his / her blood relatives
to health system goals of increasing quality of care and improving patient outcomescontribute substantiallyto health system goals of increasing quality of care and improving patient outcomes
to help you provide effective patient caredesignedto help you provide effective patient care
to grow according to forecasts shared in 2015setto grow according to forecasts shared in 2015